ReviewPharmacoEconomics2011

Cost benefit and cost effectiveness of antifungal prophylaxis in immunocompromised patients treated for haematological malignancies: reviewing the available evidence.

Petros Pechlivanoglou et al.PubMed ↗Publisher ↗

No numbers read from the abstract.